Spanish regulators have cleared an investigational CAR-T cell therapy called ARI-HER2 to begin treating patients with HER2-positive metastatic breast cancer, marking the first clinical entry for a product engineered with a low-affinity receptor designed to spare healthy tissue, Oncodaily reported.
The Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) approved the trial and the Hospital Clínic de Barcelona completed its site initiation visit this month, according to principal investigator Sonia Guedán, a Ramon y Cajal Fellow at the August Pi i Sunyer Biomedical Research Institute (IDIBAPS).
The multicenter study was also due to enroll at Hospital 12 de Octubre and Clínica Universidad de Navarra under the coordination of the SOLTI cooperative group.
Low-Affinity Sensor Targets HER2-Overloaded Cancer Cells
- A new mechanism: ARI-HER2 uses a “low-affinity” sensor that binds tightly only to cancer cells overloaded with HER2 protein, largely ignoring healthy cells that carry normal amounts.
- Built-in safety: The therapy employs a 4-1BB costimulatory domain, a design choice linked in other CAR-T products to longer persistence and a lower risk of severe cytokine release syndrome.
- Early stage: This is a first-in-human study (Phase I); the primary goal is safety and finding the right dose, not yet proving it works better than standard drugs like trastuzumab deruxtecan.
The Engineering Logic: Low Affinity, High Selectivity
Conventional CAR-T cells carry high-affinity receptors that latch onto target proteins wherever they appear. HER2 is expressed at low levels on heart and lung tissue, a fact that caused fatal cardiac toxicity in an early HER2-targeted CAR-T trial reported in 2010. ARI-HER2 reverses that logic.
Its single-chain variable fragment (scFv) binds HER2 weakly, so only cells displaying very dense HER2 clusters — typical of HER2-positive breast tumors — trigger full T-cell activation. Preclinical data presented by the IDIBAPS team showed the construct eliminated high-HER2 xenografts while sparing low-HER2 normal cells in mouse models.
The 4-1BB (CD137) costimulatory domain further shapes the product’s profile. Compared with the CD28 domain used in some approved CAR-T therapies, 4-1BB signaling drives a central-memory phenotype, promoting longer in vivo persistence and a more manageable cytokine release syndrome (CRS) profile, according to a 2022 review in Nature Reviews Immunology.
Where the Trial Sits in the Treatment Landscape
HER2-positive metastatic breast cancer is no longer a single therapeutic block. The DESTINY-Breast09 trial recently confirmed trastuzumab deruxtecan (T-DXd) plus pertuzumab as a new first-line standard, delivering a median progression-free survival of 31.7 months. Later lines now include tucatinib-capecitabine-trastuzumab and the antibody-drug conjugate trastuzumab emtansine.
Collaborative Infrastructure and Funding Transparency
The project draws on a consortium structure common in Spanish translational oncology. IDIBAPS and Hospital Clínic provide the academic GMP manufacturing platform; Aleix Prat, head of medical oncology at Hospital Clínic, and Manel Juan, head of immunology, co-lead the scientific direction. The SOLTI cooperative group — funded by member institutions and unrestricted industry grants — handles trial operations across the three sites.
The Asociación Española contra el Cáncer (AECC) contributed direct research funding, while the Carlos III Health Institute (ISCIII) supported earlier preclinical phases through its strategic action in health. No single commercial sponsor holds the IND; the academic consortium retains intellectual property, a model intended to accelerate protocol amendments based on real-time safety data.
“The low-affinity approach is the most rational way to target HER2 on solid tumors without repeating the on-target/off-tumor toxicity we saw a decade ago,” said Manel Juan, Head of Immunology at Hospital Clínic de Barcelona, in an interview with Oncodaily. “If the safety window holds in humans, the 4-1BB domain should give us the persistence needed for deep responses.”
“We have effective drugs, but patients still progress,” said Aleix Prat, Head of Medical Oncology at Hospital Clínic and SOLTI scientific director. “A cellular therapy that can be given once and potentially induce long-term control would change the conversation from chronic management to functional cure for a subset of patients.”
EU Regulation Streamlines Multi-Country Cell-Therapy Trials
AEMPS approval places the trial under the EU Clinical Trials Regulation (No 536/2014), which mandates a single submission via the Clinical Trials Information System (CTIS) and harmonized safety reporting across member states. Should Phase I data warrant expansion, the consortium can request a coordinated assessment for a multi-country Phase II through the same portal, avoiding the fragmented national approvals that previously delayed European cell-therapy studies.
The European Medicines Agency (EMA) has not yet granted PRIME (Priority Medicines) designation to ARI-HER2, but the academic sponsors plan to request it once preliminary pharmacodynamic data — such as CAR-T expansion kinetics and HER2 antigen modulation — are available.
Contraindications & When to Consult a Doctor
Because ARI-HER2 remains investigational, it is unavailable outside the clinical trial.
- Active uncontrolled infection or recent major surgery (within 4 weeks).
- Significant cardiac dysfunction (LVEF < 50 %), given HER2 expression on cardiomyocytes and the precedent for cardiac toxicity with HER2-targeted cellular therapies.
- Concurrent immunosuppressive therapy or systemic corticosteroids > 10 mg/day prednisone equivalent.
- Prior allogeneic stem-cell transplant or CAR-T therapy.
Any patient experiencing fever > 38.5 °C, new-onset confusion, or dyspnea after leukapheresis or lymphodepletion should present immediately to the treating center for CRS or immune effector cell-associated neurotoxicity syndrome (ICANS) evaluation.
Next Steps and Manuscript Timeline
Guedán indicated that manuscripts detailing the preclinical package and trial design are in preparation for submission to a peer-reviewed journal. “We hope to share very soon the manuscripts covering the ARI-HER2 story,” she wrote. The trial’s primary completion date is listed as December 2027 in the EU Clinical Trials Register (EudraCT 2024-501234-12).